768 results match your criteria: "National Hospital Organization Kyushu Cancer Center.[Affiliation]"
Correction: Thoracic and cardiovascular surgeries in Japan during 2020 : Annual report by the Japanese Association for Thoracic Surgery.
Gen Thorac Cardiovasc Surg
January 2025
Osaka University, Graduate School of Medicine, Osaka Police Hospital, Osaka, Japan.
Impact of Relative Dose Intensity of Enfortumab Vedotin for Advanced Urothelial Carcinoma.
In Vivo
December 2024
Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Background/aim: The impact of enfortumab vedotin (EV) dose reduction and/or interruption on its efficacy for advanced urothelial carcinoma (UC) is unclear.
Patients And Methods: We retrospectively analyzed consecutive patients with advanced UC who received EV after the failure of platinum-based chemotherapy and immune checkpoint inhibitors from December 2021 to June 2024. Patients were categorized into three groups based on the calculated relative dose intensity (RDI): RDI<50%, RDI ≥50 to <80%, and RDI ≥80%.
Correction: Thoracic and cardiovascular surgeries in Japan during 2021 : Annual report by the Japanese Association for Thoracic Surgery.
Gen Thorac Cardiovasc Surg
December 2024
Department of General Thoracic Surgery, Dokkyo Medical University, Tochigi, Japan.
Correction: Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter retrospective study.
Cancer Immunol Immunother
December 2024
Department of Pharmacy, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Prevalence and clinicopathological features of microsatellite instability-high metastatic or recurrent gastric and esophagogastric junction cancer: WJOG13320GPS.
Gastric Cancer
December 2024
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Background: Microsatellite instability (MSI)-high tumors represent a distinct, small-fraction subtype in esophagogastric junction cancer or gastric cancer (GC), yet their clinical significance remains poorly understood. This study aimed to investigate the prevalence and clinicopathological features of chemotherapy-naïve metastatic or recurrent MSI-high GC as a prescreening study for a phase II trial of nivolumab plus ipilimumab.
Methods: Key inclusion criteria included metastatic or recurrent adenocarcinoma of GC, ECOG performance status of 0 or 1, and no prior systemic therapy for metastatic or recurrent disease.
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.
N Engl J Med
December 2024
From Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (K.L.J.); University Hospitals Leuven, Leuven, Belgium (P.N.); Hospital María Curie, Buenos Aires (M.L.C.); Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (S.-B.K.); National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan (E.T.); Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Brussels (P.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona (C.S.); Baylor University Medical Center, Texas Oncology, U.S. Oncology, Dallas (J.O.); the Breast Center, Department of Obstetrics and Gynecology and Comprehensive Cancer Center Munich, Ludwig Maximilians University Munich University Hospital, Munich, Germany (N.H.); the University of North Carolina at Chapel Hill, Chapel Hill (L.A.C.); the University of Milan, Milan (G.C.); the European Institute of Oncology, IRCCS, Milan (G.C.); Hospital Arnau de Vilanova, Valencia, Spain (A.L.-C.); Garvan Institute of Medical Research and University of New South Wales, Sydney (E.L.); Hospital de Oncología, Centro Médico Nacional Siglo XXI, Mexico City (M.L.G.T.); Yonsei University College of Medicine, Seoul, South Korea (J.S.); the Mastology Department, Women's Health Hospital, São Paulo (A.M.); Harbin Medical University Cancer Hospital, Harbin, China (Q.Z.); National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei (C.-S.H.); the Division of Breast Surgery, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan (C.-C.H.); Filios Alta Medicina, Monterrey, Mexico (J.L.M.R.); the Medical Oncology Department, Hospital Universitario Virgen del Rocío, Seville, Spain (M.R.B.); the Department of Breast Surgery, Chiba Cancer Center Hospital, Chiba, Japan (R.N.); Eli Lilly, Indianapolis (K.R.P., C.C.L., E.B., S.C., X.A.W., L.M.S.); and Institut Curie and University of Versailles Saint-Quentin-en-Yvelines-Paris-Saclay University, Paris (F.-C.B.).
Background: Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα ().
Methods: In a phase 3, open-label trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer that recurred or progressed during or after aromatase inhibitor therapy, administered alone or with a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. Patients were assigned in a 1:1:1 ratio to receive imlunestrant, standard endocrine monotherapy, or imlunestrant-abemaciclib.
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.
J Clin Oncol
November 2024
Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.
Article Synopsis
- The study compared the combination of lenvatinib and pembrolizumab (len + pembro) with traditional chemotherapy for advanced or recurrent endometrial cancer (aEC) in patients who had not previously been treated.
- Results showed that while len + pembro did not statistically outperform chemotherapy in terms of progression-free survival (PFS) or overall survival (OS), it offered similar outcomes, indicating noninferiority.
- The trial involved 842 patients and found median PFS and OS were comparable between the two treatment groups, suggesting len + pembro could be an effective alternative to chemotherapy for this cancer type.
Clinical significance of NOTCH1 and FBXW7 alterations in adult T-cell leukemia/lymphoma.
Int J Hematol
November 2024
Department of Pathology and Molecular Diagnostics, Graduate School of Medical Sciences, Nagoya City University, 1-Kawasumi, Mizuho-Ku, Nagoya, 467-8601, Japan.
Here, we investigated the clinical significance of NOTCH1 and FBXW7 alterations for adult T-cell leukemia/lymphoma (ATLL) treatment outcomes. NOTCH1 alterations were identified in 37 (14.4%) of 257 patients, of which 33 were single nucleotide variants/insertion-deletions in the PEST domain, and 7 were in the heterodimerization or LIN-12/Notch repeats domains.
View Article and Find Full Text PDFPhoton and Neutron Dose Estimation Using Monte Carlo Simulation in TrueBeam's Room.
J Med Phys
September 2024
Department of Health Sciences, Division of Medical Quantum Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Purpose: The distribution of neutron ambient dose equivalent within the TrueBeam 10 MV photon chamber was investigated.
Materials And Methods: The research used particle and heavy ion transport code system (PHITS) code and JENDL-5.0 to simulate the neutron ambient dose equivalent on and around TrueBeam's head.
Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysis.
Cancer Med
November 2024
Department of Urology, Toho University Sakura Medical Center, Sakura, Japan.
Article Synopsis
- Darolutamide combined with androgen-deprivation therapy (ADT) and docetaxel significantly lowered the risk of death by 32.5% in the ARASENS study, indicating its effectiveness for treating metastatic hormone-sensitive prostate cancer (mHSPC).
- In the Japanese subgroup analysis of 148 patients, higher percentages of participants were older (≥75 years) and had lower body mass indexes compared to the overall study population, but the treatment showed a similar safety and efficacy profile.
- While overall survival trends were positive for darolutamide in Japanese patients, the combined treatment was well tolerated, with no new safety concerns identified, despite some patients experiencing more frequent adverse events like neutropenia.
Different efficacy of tyrosine kinase inhibitors by KIT and PGFRA mutations identified in circulating tumor DNA for the treatment of refractory gastrointestinal stromal tumors.
BJC Rep
July 2024
Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.
Background: While advanced gastrointestinal stromal tumors (GISTs) are primarily treated with tyrosine kinase inhibitors (TKIs), acquired resistance from specific mutations in KIT or PDGFRA frequently occurs. We aimed to assess the utility of circulating tumor DNA (ctDNA) as a modality of therapeutic decision-making in advanced GIST.
Methods: We conducted a pooled analysis of SCRUM-Japan studies for advanced GIST patients.
Prevalence of falls in the last weeks of life and relationship between falls, independence and quality of dying in Japan: a large prospective cohort study.
BMJ Open
November 2024
Palliative and Supportive Care Division, Seirei Mikatahara Hospital, Hamamatsu, Japan.
Article Synopsis
- The study investigates the frequency and complications of falls in palliative care units (PCUs) for advanced cancer patients and how these relate to independence and quality of dying.
- Among 1,633 patients observed, 150 (9.2%) experienced falls in the last month of life, primarily due to needing to use the toilet, with serious injuries being very rare.
- The findings suggest that while falls can be common, they are not necessarily harmful and may reflect a patient's independence, indicating that healthcare providers should balance fall prevention with supporting patient autonomy.
Fibroblast growth factor receptors (FGFRs) are a highly conserved family of transmembrane receptor tyrosine kinases with multiple roles in the regulation of key cellular processes. Specific FGFR mutations have been observed in several types of cancers, including gastric carcinoma and cholangiocarcinoma. Dose escalation data of 24 Japanese patients with solid tumors treated with Tasurgratinib (previously known as E7090), a potent, selective FGFR1-3 inhibitor, was reported in a phase I, first-in-human, single-center study.
View Article and Find Full Text PDFKnowledge and Awareness of Cancer Genome Profiling Tests among Japanese Patients with Cancer.
Clin Pract
October 2024
School of Nursing, Tsuruga Nursing University, Tsuruga 914-0814, Japan.
(1) Background: The number of patients with cancer undergoing cancer genome profiling is increasing; however, it remains unclear how accurately they understand the details of the tests and treatments. This study aimed to clarify the awareness of cancer genome profiling tests among patients with cancer who visited cancer genome medical clinics. (2) Methods: A questionnaire survey was conducted on awareness, anxiety, sources of information, and psychological states concerning cancer genome profiling tests.
View Article and Find Full Text PDFClinical Significance of a Prospective Large Genomic Screening for SCLC: The Genetic Classification and a Biomarker-Driven Phase 2 Trial of Gedatolisib.
J Thorac Oncol
October 2024
Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan. Electronic address:
Article Synopsis
- SCLC has traditionally been viewed as a single entity, hindering advances in treatment; however, identifying genetic differences is key to improving patient outcomes.
- A study analyzed over 1000 SCLC samples using genomic screening to identify five distinct genetic subgroups, which can respond differently to therapies, especially targeted treatments.
- The findings indicate that while certain subgroups, like the NSCLC and MYC subgroups, have poorer survival rates with standard treatments, others may benefit from specialized therapies, highlighting the importance of personalized medicine in SCLC management.
Nivolumab plus ipilimumab with chemotherapy for non-small cell lung cancer with untreated brain metastases: A multicenter single-arm phase 2 trial (NIke, LOGiK 2004).
Eur J Cancer
November 2024
Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. Electronic address:
Article Synopsis
- The study investigates the impact of dual immunotherapy (nivolumab and ipilimumab) along with platinum-based chemotherapy on patients with untreated brain metastases from non-small cell lung cancer (NSCLC).
- In total, 30 patients were enrolled, and the results showed a 50% intracranial response rate with a 20% rate of complete response, indicating effectiveness in targeting brain lesions.
- The findings suggest that this treatment combination has promising potential for managing NSCLC patients with brain metastases, achieving a median intracranial progression-free survival of 8.1 months.
ASO Author Reflections: Can Conversion Therapy be an Option for Advanced Esophageal Cancer with Distant Metastases?
Ann Surg Oncol
January 2025
Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer.
Cancer Med
September 2024
Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Background: In the phase 3 EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 study, cemiplimab significantly improved overall survival (OS) versus chemotherapy for patients with recurrent or metastatic cervical cancer who progressed after first-line platinum-based chemotherapy. We present a post hoc subgroup analysis of patients enrolled in Japan.
Methods: Patients were enrolled regardless of programmed cell death-ligand 1 status and randomized 1:1 to cemiplimab 350 mg intravenously every 3 weeks or investigator's choice single-agent chemotherapy for up to 96 weeks.
Early defibrotide therapy and risk factors for post-transplant veno-occlusive disease/sinusoidal obstruction syndrome in childhood.
Pediatr Blood Cancer
December 2024
Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Article Synopsis
- Veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), is a serious complication that can occur after hematopoietic cell transplantation (HCT), especially in pediatric patients.
- A study at Kyushu University Hospital evaluated the effects of early defibrotide (DF) therapy on children with VOD/SOS after HCT, revealing that VOD/SOS was more common in patients treated post-DF introduction, likely due to higher cases of relapsed/refactory acute lymphoblastic leukemia (ALL).
- Findings suggest that starting DF therapy early based on specific diagnostic criteria significantly lessens the severity of VOD/SOS and improves survival, although the overall incidence of VOD/SOS
A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer.
Future Oncol
November 2024
University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Article Synopsis
- The CAPItello-291 study examined the effectiveness of the drug combination capivasertib and fulvestrant in treating advanced HR-positive, HER2-negative breast cancer in patients whose cancer progressed after previous treatments.
- Results indicated that patients receiving the capivasertib plus fulvestrant treatment experienced longer progression-free survival (7.2 months) compared to those receiving placebo plus fulvestrant (3.6 months).
- Common side effects included diarrhea and rashes, but the study is still ongoing, and more results are anticipated in the future.
Safety and Efficacy of Conversion Therapy After Systemic Chemotherapy in Advanced Esophageal Cancer with Distant Metastases: A Multicenter Retrospective Observational Study.
Ann Surg Oncol
January 2025
Department of Surgery, Keio University School of Medicine, Shinjuku, Japan.
Article Synopsis
- Conversion therapy, involving surgery or chemoradiotherapy, is being explored for treating esophageal squamous cell carcinoma (ESCC) patients with distant metastases, which were previously considered incurable.
- A study reviewed 147 patients who underwent conversion therapy, revealing that most had major complications post-surgery, but overall survival rates were promising, with a 5-year survival rate of 31.7% for patients who responded to treatment.
- The research concluded that conversion therapy for ESCC with distant metastasis is not only safe but also may lead to better patient outcomes, particularly for those who show a positive response to treatment.
A nationwide survey on the safety of cricothyrotomy: a multicenter retrospective study in Japan.
Esophagus
September 2024
Department of Otolaryngology, Head and Neck Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Article Synopsis
- Cricothyrotomy is a procedure used to secure an airway in emergency situations and can also help patients expel sputum; however, its overall safety and effectiveness are still being evaluated.
- A nationwide survey in Japan involved data from 1,001 patients across 116 healthcare facilities between 2010 and 2021, highlighting that most cricothyrotomies (94.4%) were performed for sputum suctioning post-surgery, primarily after esophagectomy.
- Results indicated lower complication rates for sputum suctioning compared to emergency airway clearance, suggesting that cricothyrotomy is safer for patients recovering from esophagectomy, but additional research is necessary to confirm its benefits.
Impact of COVID-19 pandemic on bone and soft tissue sarcoma patients' consultation and diagnosis.
Sci Rep
September 2024
Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
The coronavirus disease (COVID-19) pandemic negatively affected the diagnosis and treatment of several cancer types. However, this pandemic's exact impact and extent on bone and soft tissue sarcomas need to be clarified. We aimed to investigate the effect of the COVID-19 pandemic and emergency declaration by the local government on consultation behavior and clinical stage at diagnosis of bone and soft tissue sarcoma.
View Article and Find Full Text PDFClinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer.
Br J Cancer
October 2024
Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Article Synopsis
- The study focuses on using circulating tumor DNA (ctDNA) analysis to identify homologous recombination deficiency (HRD) and BRCA1/2 and ATM mutations in patients with advanced pancreatic cancer (APC).
- Out of 702 APC patients analyzed, 4.8% had BRCA1/2 mutations and 4.4% had ATM mutations, with those having BRCA mutations showing significantly better response rates to platinum-based chemotherapy compared to those without.
- ctDNA profiling is suggested as a valuable, non-invasive method for assessing mutation status and selecting appropriate treatments in advanced pancreatic cancer, offering a practical approach to HRD screening.
Outcome of hepatectomy after systemic therapy for hepatocellular carcinoma: a Japanese multicenter study.
Surg Today
August 2024
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Background And Purpose: In recent years, new systemic therapies have been developed for hepatocellular carcinoma (HCC). The aim of this study was to evaluate the prognosis of patients with unresectable HCC treated with R0 hepatectomy after systemic therapy.
Methods: Data from 27 patients who underwent hepatectomy for HCC after systemic therapy at six facilities were analyzed retrospectively.